Skip to content
TrackPodcasts
scienceFeb 3, 202444:08pending

TWiV 1084: Clinical update with Dr. Daniel Griffin

About this episode

In his weekly clinical update, Dr. Griffin discusses the how the pandemic influenced the healthcare job market before he reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses the safety of the prefusion RSV vaccine, if high or moderate dose of the quadrivalent influenza vaccine is better for protection against hospitalization, summarizes the new WHO COVID guidelines, revisits how to prevent pathogen transmission in healthcare setting, the under use of COVID oral antiviral and what occurs in persistently SARS-CoV-2 infected cells in culture after antiviral treatment, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how inflammatory markers change correlate with death when in ICU and if cognitive slowing is part of long COVID-19.

Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

Get every episode summarized

Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

TWiV 1084: Clinical update with Dr. Daniel Griffin

This Week in Virology

0:00
44:08

More episodes

More from This Week in Virology

View all episodes →